Strategy for selection of clinical doses for SBT101, a gene therapy for the treatment of adrenomyeloneuropathy (AMN)
Time: 2:30 pm
day: Day One: Track B PM
Details:
- Selection of AAV vector and delivery for AMN
- How target engagement and efficacy studies supported starting dose
- Safety studies further supported dose selection
